US SB1785

Eliminates tax deductions for direct-to-consumer advertising expenses on prescription drugs and compounded drugs under new Section 280I of the Internal Revenue Code

Covers advertising through television, radio, telephone, direct mail, billboards, internet, social media, mobile apps, and digital platforms

Exempts advertisements published in journals and other periodicals from the deduction prohibition

Applies to drug sponsors and owners of outsourcing facilities, including indirect ownership through subsidiaries

Takes effect for advertising expenses paid or incurred after the date of enactment